Sign in Subscribe
Biological products industry

Lenacapavir Shows Promise in Treating Multidrug-Resistant HIV-1

Strategic Insights

— 1 min read

Researchers have made a significant breakthrough in treating multidrug-resistant HIV-1 infection with the long-acting human immunodeficiency virus type 1 (HIV-1) capsid inhibitor, lenacapavir. In a phase 2/3 trial conducted by Yale University, 44 out of 71 participants showed a significant decrease in HIV-1 RNA levels, from 64% at baseline to 29% at week 104, indicating the efficacy of lenacapavir in combination with an optimized background regimen.

Key Takeaways:

  • The phase 2/3 trial involved 72 adults living with multidrug-resistant HIV-1, with 44 participants showing a significant decrease in HIV-1 RNA levels at week 104.
  • Lenacapavir was administered subcutaneously every 26 weeks in combination with an investigator-selected optimized background regimen.
  • The trial showed a 62% reduction in HIV-1 RNA levels among the participants, with 14 participants developing treatment-emergent lenacapavir resistance.
  • The researchers noted that lenacapavir represents an important treatment option for people with multidrug-resistant HIV-1.
  • The trial was conducted internationally, with 42 sites participating, and received financial support from Gilead Sciences.
  • Additional information on the trial can be obtained from Onyema Ogbuagu at Yale University.

Statistics:

  • 72 adults living with multidrug-resistant HIV-1 participated in the trial.
  • 44 out of 71 participants showed a significant decrease in HIV-1 RNA levels at week 104.
  • HIV-1 RNA levels decreased from 64% at baseline to 29% at week 104.
  • 14 participants developed treatment-emergent lenacapavir resistance, with 7 resuppressing.

Sources:

- Efficacy and Safety of Long-acting Subcutaneous Lenacapavir In Heavily Treatment-experienced People With Multidrug-resistant Hiv-1: Week 104 Results of a Phase 2/3 Trial. Clinical Infectious Diseases, 2024.

- Oxford University Press Inc, Journals Dept, 2001 Evans Rd, Cary, NC 27513, USA.

- Yale University, School of Medicine, 333 Cedar St, New Haven, CT 06510, United States.

Read more